AI Terminal
NUFORMIX PLC
Environmental & Social Information • Feb 15, 2023
4941_rns_2023-02-15_36c67f26-0572-4a38-a39a-4aa76eb75f86.html
Environmental & Social Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 8876P
Nuformix PLC
15 February 2023
REACH
15 February 2023
Nuformix plc
("Nuformix" or the "Company" or the "Group")
NXP002 Update
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the following update regarding the Company's NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF").
As previously announced, the Company has initiated studies in 3D human IPF lung tissue using a disease and species relevant model, and is working with its partner, Fibrofind, focusing on NXP002 in combination with current standards of care. Suitable human disease tissue, which is highly limited in supply, has now been acquired allowing the practical elements of the study to commence, with results and further updates to be announced in due course.
NXP002 combinations have already shown promise in human diseased IPF tissue, showing a pleasing synergistic efficacy effect with low doses of standards-of-care, resulting in the Group filing a new combination patent application in 2022.
Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "We've had to wait a little longer than expected to acquire suitable tissue, but I'm delighted that the main element of this key study, further evaluating NXP002 combination therapies is now underway and I look forward to sharing the results when they are available."
Enquiries:
| Nuformix plc | |
| Dr Dan Gooding, Executive Director | Via IFC Advisory |
| Stanford Capital Partners Limited | |
| Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
| John Howes (Corporate Broking) | +44 (0) 20 3650 3652 |
| IFC Advisory Limited | |
| Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 [email protected] |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
About Fibrosis
Fibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Whilst fibrosis treatments are in their infancy the emerging lung fibrosis market demonstrates their blockbuster potential. Idiopathic Pulmonary Fibrosis is classified as a rare disease and presents a global commercial market that is forecast to grow to US$5bn by 2025. Sales of standard-of-care therapies OFEV and Esbriet achieved US$2.58bn and US$1.04bn respectively in 2021.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRABZLFFXLLZBBK